136 related articles for article (PubMed ID: 23757212)
41. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
42. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
[TBL] [Abstract][Full Text] [Related]
43. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
[TBL] [Abstract][Full Text] [Related]
44. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
Berg SL; Blaney SM; Devidas M; Lampkin TA; Murgo A; Bernstein M; Billett A; Kurtzberg J; Reaman G; Gaynon P; Whitlock J; Krailo M; Harris MB;
J Clin Oncol; 2005 May; 23(15):3376-82. PubMed ID: 15908649
[TBL] [Abstract][Full Text] [Related]
46. Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study.
González-Vicent M; Molina B; Andión M; Sevilla J; Ramirez M; Pérez A; Díaz MA
Eur J Haematol; 2011 Jul; 87(1):46-53. PubMed ID: 21692851
[TBL] [Abstract][Full Text] [Related]
47. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
48. [Transplantation of highly purified CD34+ hematologic peripheral stem cells from haploidentical related donors in the treatment of children with non-malignant diseases].
Starý J; Sedlácek P; Vodvárková S; Poloucková A; Formánková R; Gasová Z; Marinov I
Cas Lek Cesk; 2002 Mar; 141(6):176-81. PubMed ID: 11977835
[TBL] [Abstract][Full Text] [Related]
49. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
[TBL] [Abstract][Full Text] [Related]
50. [Hematopoietic stem cell transplantation with busulfanthiotepa-cyclophosphamide conditioning for pediatric patients with high-risk acute lymphoblastic leukemia].
Umeda K; Lin YW; Watanabe K; Adachi S; Usami I; Akiyama Y; Kubota M; Nakahata T
Rinsho Ketsueki; 2001 Sep; 42(9):685-90. PubMed ID: 11680979
[TBL] [Abstract][Full Text] [Related]
51. A single centre experience with allogeneic stem cell transplantation for severe aplastic anaemia in childhood.
Ladenstein R; Peters C; Minkov M; Emminger-Schmidmeier W; Mann G; Höcker P; Hawliczek R; Rosenmayr A; Fink FM; Niederwieser D; Gadner H
Klin Padiatr; 1997; 209(4):201-8. PubMed ID: 9293451
[TBL] [Abstract][Full Text] [Related]
52. Allogeneic stem cell transplantation in children with acute lymphoblastic leukemia after isolated central nervous system relapse: our experiences and review of the literature.
Yoshihara T; Morimoto A; Kuroda H; Imamura T; Ishida H; Tsunamoto K; Naya M; Hibi S; Todo S; Imashuku S
Bone Marrow Transplant; 2006 Jan; 37(1):25-31. PubMed ID: 16247416
[TBL] [Abstract][Full Text] [Related]
53. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin.
Dong L; Wu T; Zhang MJ; Gao ZY; Lu DP
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1515-24. PubMed ID: 18022582
[TBL] [Abstract][Full Text] [Related]
54. HLA-haploidentical umbilical cord blood stem cell transplantation in a child with advanced leukemia: clinical outcome and analysis of hematopoietic recovery.
Miniero R; Busca A; Roncarolo MG; Saitta M; Iavarone A; Timeus F; Biondi A; Amoroso A; Perugini L; Ciuti E
Bone Marrow Transplant; 1995 Aug; 16(2):229-40. PubMed ID: 7581141
[TBL] [Abstract][Full Text] [Related]
55. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
56. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.
Mohty M; Bilger K; Jourdan E; Kuentz M; Michallet M; Bourhis JH; Milpied N; Sutton L; Jouet JP; Attal M; Bordigoni P; Cahn JY; Sadoun A; Ifrah N; Guyotat D; Faucher C; Fegueux N; Reiffers J; Maraninchi D; Blaise D
Leukemia; 2003 May; 17(5):869-75. PubMed ID: 12750699
[TBL] [Abstract][Full Text] [Related]
57. Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors?
Ruggeri A; Ciceri F; Gluckman E; Labopin M; Rocha V;
Best Pract Res Clin Haematol; 2010 Jun; 23(2):207-16. PubMed ID: 20837332
[TBL] [Abstract][Full Text] [Related]
58. Studies of decitabine with allogeneic progenitor cell transplantation.
Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
Leukemia; 1997 Mar; 11 Suppl 1():S32-4. PubMed ID: 9130690
[TBL] [Abstract][Full Text] [Related]
59. Successful non-T-cell-depleted HLA-haploidentical stem cell transplantation (SCT) with reduced-intensity conditioning from a second child for late graft failure after the first HLA-haploidentical SCT for MDS/overt leukemia based on feto-maternal microchimerism.
Fuchida S; Nakano S; Yamada N; Uchida R; Okano A; Okamoto M; Maruya E; Saji H; Shimazaki C
Bone Marrow Transplant; 2005 May; 35(10):1031-2. PubMed ID: 15806124
[No Abstract] [Full Text] [Related]
60. Self-reported quality of life in long-term survivors of childhood lymphoblastic malignancy treated with hematopoietic stem cell transplantation versus conventional therapy.
Sundberg KK; Wettergren L; Frisk P; Arvidson J
Pediatr Blood Cancer; 2013 Aug; 60(8):1382-7. PubMed ID: 23519958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
